​

Outlook Therapeutics (OTLK) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChart

OTLK Stock Forecast

Outlook Therapeutics (OTLK) stock forecast, based on 14 Wall Street analysts, predicts a 12-month average price target of $1.00, with a high of $1.00 and a low of $1.00. This represents a -24.81% decline from the last price of $1.33.

- $3 $6 $9 $12 $15 High: $1 Avg: $1 Low: $1 Last Closed Price: $1.33

OTLK Stock Rating

Outlook Therapeutics stock's rating consensus is Buy, based on 14 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 8 Buy (57.14%), 6 Hold (42.86%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 14 0 6 8 Strong Sell Sell Hold Buy Strong Buy

OTLK Price Target Upside V Benchmarks

TypeNameUpside
StockOutlook Therapeutics-24.81%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts-11
Avg Price Target-$1.00$1.00
Last Closing Price$1.33$1.33$1.33
Upside/Downside--24.81%-24.81%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Oct, 25-23--5
Sep, 25-23--5
Aug, 25131--5
Jul, 25131--5
Jun, 25141--6
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Aug 29, 2025Douglas TsaoH.C. Wainwright$1.00$1.09-8.26%-24.81%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Aug 29, 2025GuggenheimBuyNeutraldowngrade
May 20, 2025GuggenheimBuyBuyhold
Nov 29, 2024H.C. WainwrightBuyBuyhold
Nov 29, 2024BTIGBuyBuyhold
May 17, 2024H.C. WainwrightBuyBuyhold
Mar 27, 2024BTIGBuyupgrade
Jan 25, 2024GuggenheimBuyupgrade
Jan 25, 2024Brookline CapitalBuyupgrade
Dec 29, 2023AscendiantBuyBuyhold
Nov 03, 2023H.C. WainwrightBuyupgrade

Financial Forecast

EPS Forecast

$-5K $-4K $-3K $-2K $-500 $500 Sep 21 Sep 23 Sep 24 Sep 25 Sep 26 Sep 27 Sep 28 Sep 29
Sep 21Sep 23Sep 24Sep 25Sep 26Sep 27Sep 28Sep 29
Reported$-6.96$-4.72$-4.06K-----
Avg Forecast$-8.67$-4.80$-4.91$-2.08$-0.30$1.01$1.84$2.31
High Forecast$-4.08$-4.17$-4.76$-1.63$-0.26$1.09$2.09$2.63
Low Forecast$-15.54$-5.43$-5.16$-2.55$-0.34$0.92$1.59$1.99
Surprise %-19.72%-1.67%82652.75%-----

Revenue Forecast

$0 $50M $100M $150M $200M $250M Sep 21 Sep 23 Sep 24 Sep 25 Sep 26 Sep 27 Sep 28 Sep 29
Sep 21Sep 23Sep 24Sep 25Sep 26Sep 27Sep 28Sep 29
Reported--------
Avg Forecast$200.00K$2.18M$237.67K$9.42M$49.58M$113.86M$166.00M$189.00M
High Forecast$322.07K$2.41M$262.97K$14.21M$50.44M$119.78M$183.67M$209.12M
Low Forecast$118.52K$1.94M$212.39K$4.52M$48.70M$107.94M$148.34M$168.90M
Surprise %--------

Net Income Forecast

$-80T $-63T $-46T $-29T $-12T $5T Sep 21 Sep 23 Sep 24 Sep 25 Sep 26 Sep 27 Sep 28 Sep 29
Sep 21Sep 23Sep 24Sep 25Sep 26Sep 27Sep 28Sep 29
Reported$-53.16M$-58.98M$-75.37T-----
Avg Forecast$-108.41M$-89.03M$-92.05M$-38.79M$-5.57M$18.64M$34.13M$42.85M
High Forecast$-50.99M$-77.42M$-88.38M$-30.21M$-4.80M$20.22M$38.85M$48.78M
Low Forecast$-194.43M$-100.65M$-95.72M$-47.37M$-6.33M$17.06M$29.41M$36.92M
Surprise %-50.96%-33.75%81877417.58%-----

OTLK Forecast FAQ

Is Outlook Therapeutics stock a buy?

Outlook Therapeutics stock has a consensus rating of Buy, based on 14 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 8 Buy, 6 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Outlook Therapeutics is a favorable investment for most analysts.

What is Outlook Therapeutics's price target?

Outlook Therapeutics's price target, set by 14 Wall Street analysts, averages $1 over the next 12 months. The price target range spans from $1 at the low end to $1 at the high end, suggesting a potential -24.81% change from the previous closing price of $1.33.

How does Outlook Therapeutics stock forecast compare to its benchmarks?

Outlook Therapeutics's stock forecast shows a -24.81% downside, underperforming the average forecast for the healthcare stocks sector (15.45%) and underperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Outlook Therapeutics over the past three months?

  • October 2025: 0% Strong Buy, 40.00% Buy, 60.00% Hold, 0% Sell, 0% Strong Sell.
  • September 2025: 0% Strong Buy, 40.00% Buy, 60.00% Hold, 0% Sell, 0% Strong Sell.
  • August 2025: 20.00% Strong Buy, 60.00% Buy, 20.00% Hold, 0% Sell, 0% Strong Sell.

What is Outlook Therapeutics’s EPS forecast?

Outlook Therapeutics's average annual EPS forecast for its fiscal year ending in September 2025 is $-2.08, marking a -99.95% decrease from the reported $-4.063K in 2024. Estimates for the following years are $-0.3 in 2026, $1.01 in 2027, $1.84 in 2028, and $2.31 in 2029.

What is Outlook Therapeutics’s revenue forecast?

Outlook Therapeutics's average annual revenue forecast for its fiscal year ending in September 2025 is $9.42M, reflecting a 0% decrease from the reported $0 in 2024. The forecast for 2026 is $49.58M, followed by $113.86M for 2027, $166M for 2028, and $189M for 2029.

What is Outlook Therapeutics’s net income forecast?

Outlook Therapeutics's net income forecast for the fiscal year ending in September 2025 stands at $-38.79M, representing a -100.00% decrease from the reported $-75.367T in 2024. Projections indicate $-5.565M in 2026, $18.64M in 2027, $34.13M in 2028, and $42.85M in 2029.